A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides
about
Novel Strategies in the Prevention and Treatment of Urinary Tract InfectionsPrevention of anti-microbial peptide LL-37-induced apoptosis and ATP release in the urinary bladder by a modified glycosaminoglycanLL-37 induced cystitis and the receptor for advanced glycation end-products (RAGE) pathway.Interplay between bladder microbiota and urinary antimicrobial peptides: mechanisms for human urinary tract infection risk and symptom severity.Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice.Cathelicidin augments epithelial receptivity and pathogenesis in experimental Escherichia coli cystitis.NAD(P)H:quinone oxidoreductase 1 protects bladder epithelium against painful bladder syndrome in mice.Physiological relevance of LL-37 induced bladder inflammation and mast cells.Topical cathelicidin (LL-37) an innate immune peptide induces acute olfactory epithelium inflammation in a mouse model.Restoring the glycosaminoglycans layer in recurrent cystitis: experimental and clinical foundations.Amplifying renal immunity: the role of antimicrobial peptides in pyelonephritis.Cutaneous Burn Injury Modulates Urinary Antimicrobial Peptide Responses and the Urinary Microbiome.Bladder pain in an LL-37 interstitial cystitis and painful bladder syndrome model.A tunable hydrogel system for long-term release of cell-secreted cytokines and bioprinted in situ wound cell delivery.Prevention of sinonasal inflammation by a synthetic glycosaminoglycan.IL-33 mast cell axis is central in LL-37 induced bladder inflammation and pain in a murine interstitial cystitis modelA synthetic glycosaminoglycan reduces sinonasal inflammation in a murine model of chronic rhinosinusitis
P2860
Q26772924-EC3CCEA8-0BDA-4CAB-9E64-EF54CF581035Q31143378-64FB6089-5E00-4F54-A61E-6A877FFD8FB7Q33690597-482F6631-1ED4-46DC-86B5-D9503E352830Q34655040-866A6010-40D9-46D1-8BE2-EED0F8ADB79EQ34973081-757DC5E1-933C-4CF5-988D-E2BE3FA8F74DQ35197365-4B11976C-C3FB-436A-9706-80308D2740D4Q36391365-CE7E92D1-C78F-4A21-8F37-5A14276BEEF5Q37627413-9DB55B08-CD08-4F5E-B33B-95C22A02A046Q37656026-F1AAD996-2FC5-4745-BA93-25539FA1D597Q38196864-BD2A2746-6ABB-47F9-BC26-54CCCCC4A3B5Q38543398-C32B2CAE-75CB-4327-80F9-B100F9969D84Q38883379-633B48E9-878F-4AE3-BA21-F96D8C0F3385Q42374948-82D36F1B-0405-4E0C-8C90-A5507450D66EQ45037113-2CF9AE80-1E13-4459-93D3-D673BD30760EQ49774684-152586CC-BCE4-4348-BD27-BA35E4DFF467Q57136724-5AACFA1D-829B-4D32-98FE-6FF75DE5D777Q58699106-A38103C2-A216-4FFF-BE9A-D9E5E8F128D7
P2860
A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 August 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A murine model of inflammatory ...... with sulfated polysaccharides
@en
A murine model of inflammatory ...... with sulfated polysaccharides.
@nl
type
label
A murine model of inflammatory ...... with sulfated polysaccharides
@en
A murine model of inflammatory ...... with sulfated polysaccharides.
@nl
prefLabel
A murine model of inflammatory ...... with sulfated polysaccharides
@en
A murine model of inflammatory ...... with sulfated polysaccharides.
@nl
P2093
P2860
P1476
A murine model of inflammatory ...... with sulfated polysaccharides
@en
P2093
Aleksander Skardal
Glenn D Prestwich
Jianxing Zhang
Lindsi McCoard
Randal O Dull
Sean Slack
Siam Oottamasathien
Thomas P Kennedy
Wanjian Jia
P2860
P304
P356
10.1016/J.JURO.2011.03.099
P407
P433
P577
2011-08-19T00:00:00Z